Full-Time

Director – Global Biopharmaceutical Stability Operations

Global Biopharmaceutical Stability

Posted on 9/10/2025

Deadline 10/1/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$188.3k - $244.1k/yr

+ Incentive Cash + Stock Opportunities

Company Historically Provides H1B Sponsorship

Franklin Township, NJ, USA + 2 more

More locations: Princeton, NJ, USA | Devens, MA, USA

Hybrid

This position is hybrid, requiring at least 50% onsite presence.

Category
Biology & Biotech (4)
, , ,
Required Skills
Minitab
Requirements
  • Bachelor’s degree and 15+ years of experience required, preferably in chemistry, microbiology, pharmacy, or other related science discipline.
  • Master’s degree and 10 years of experience in leadership role highly desirable.
  • Strong understanding of cGMPs and regulatory requirements impacting stability programs, non-clinical statistical analysis, and laboratory information management systems.
  • Understanding of technical areas related to pharmaceutical manufacturing/packaging/distribution, chemical and microbiological analyses, statistical methods, and equipment qualification/calibration.
  • Must have demonstrated ability to plan, implement, and achieve significant, complex goals and objectives.
  • Basic understanding of financial management systems used for budget processes.
  • Expert knowledge and understanding of stability ICH Guidelines (Q1A, Q5C) and associated policies, directives and guidance documents.
  • A thorough knowledge of cGMP regulations as referenced in The Code of Federal Regulations (21CFR) and their specific application to stability programs in a pharmaceutical manufacturing facility.
  • Expert Knowledge of US/EU/ROW Requirements, Corporate Directives and industry best practices.
  • Expert Knowledge of Drug Substance and Drug Product manufacturing and good understanding of analytical and/or Microbiology methods.
  • Significant Experience with authorship and able to critically review investigations, interpret results, and generate technical conclusions consistent with Quality management principles.
  • Excellent skills to drive development of technical or scientific initiatives for solving complex problems/issues, recommending and drive science-based decisions/ implementation of solutions.
  • Significant experience on health authorities’ inspections in front room.
  • Excellent written and verbal communication skills.
  • Experience as team manager: planning and organizing, conflict management, coaching others, talent selection, developing others, decision-making, building relationships, innovation management, and resource allocation.
  • Advanced knowledge of Microsoft office applications, LIMS, Quality Management system (e.g., TrackWise or Veeva), Statistics software (e.g., SlimSTAT, JMP, Minitab).
  • Basic understanding of financial management systems used for budget processes.
Responsibilities
  • Serves as the commercial stability Global Process Owner (GPO) providing leadership for program governance, operations, escalations, and benefits realization with respect to the QMS and global Stability Level 2 processes and systems.
  • Collaborates with QMS pillar ownership, Level 1 process leads, and network GPOs, Global Process Leads, and Local Process Owners to ensure the QMS as a quality business advantage.
  • Drives continuing QMS refinement within the commercial Stability Level 2 network toward a more simplified, aligned, and agile global process.
  • Drives operational excellence initiatives within the Global Biopharmaceutical Stability team and the Global Stability Level 2 network to ensure continuous improvement, innovation, and simplification of QMS processes and procedures to support Quantum Leap.
  • Leads and oversees assignment and assessment of regulatory surveillance via the External Engagement process and ensures implementation of resulting requirements and guidance.
  • Oversees the evolution and maturation of the commercialization procedure in order to provide efficient and agile processes to stability product leads for new product and process introductions.
  • Owns the global Stability Level 2 communities of practice to collaborate and align on a future state process and procedures that will support fit-for-purpose and fit-for-speed execution in context of Quantum Leap.
  • Manages day-to-day operations of stability sample management, logistics, and enrollment across the Global Biopharmaceutical Stability network, inclusive of internal and external partners, to ensure uninterrupted sample availability and supply in support of commercial stability regulatory requirements.
  • Oversees and defines the commercial stability storage strategy to generate aligned, harmonized, or standardized operational requirements supporting risk reductions, business continuity, cost effective capacity and resource management, and efficient and compliant storage program strategies.
  • Ensures all critical and major issues, which may have an adverse effect on the quality of the product or represent a risk of supply, as a result of events that occur within the logistics areas are escalated as per standard procedures and are resolved within stated timelines (i.e. investigation/deviation and change management procedures).
  • Dedicates appropriate resources to event management related to logistics storage and enrollment strategies and operations.
  • Oversees support for the design, development, testing and implementation of IT and business solutions within the Global Biopharmaceutical Stability team.
  • Ensures appropriate resources are dedicated to product and process changes and events that may have potential impact to program LIMS systems, including: appropriate impact assessments, user requirements, testing, and deployments executed on behalf of the team.
  • Oversees the implementation of the Global Biopharmaceutical Stability trend program including initial site implementation, periodic review, and the definition and implementation of electronic solutions for the delivery of statistical trend limits.
  • Leads implementation of a quality risk management program including developing and monitoring quality metrics and ensuring all regulatory requirements are met.
  • Owns reporting and response against Level 2 and Level 1 metrics to ensure risk reductions, continuing simplification, and event escalation, as appropriate.
  • Drives definition of yearly and breakthrough objectives to ensure consistency with greater departmental and quality objectives.
  • Manages Global Biopharmaceutical Stability Book of Work to drive completion of objectives, support resource management across the team, and prioritize efforts for the advancement of the Stability Center of Excellence.
  • Provides management and coaching to direct reports to generate high performance in the execution of sample logistics and stability LIMS management.
  • Fosters a culture focused on demonstrating high capacity for executing with company values and behaviors.
  • Provide continuing development opportunities, including ongoing Performance Connections reviews.
  • Manages and controls departmental spending for the Global Biopharmaceutical Stability team establishing year-over-year budget strategies for the team.
  • Makes effective financial and operational decisions to positively impact both short and long-term business objectives.
  • Accountable for stability resources definition and budget to ensure adherence to cost allowances throughout the year.
  • Lead efforts to quantify and communicate value capture when efficiencies are put in place.
  • Works in partnership with site EHS to ensure Stability operations comply with environmental and safety regulatory standards.
  • Maintains a safe work environment by ensuring that department personnel follow site EHS policies and procedures.

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth Portfolio averages 16% YoY growth over two years per Q1 2026 results.
  • Eliquis on Cost Plus Drugs at $345/30-day expands access from April 27.
  • FoundationOne CDx expansion detects MTAP deletion for targeted oncology therapy.

What critics are saying

  • Eliquis generics from Apotex erode $14.4B sales post-2026 patent expiry.
  • Revlimid sales plunge drives 5.1% revenue drop in next 12 months.
  • FDA revoked Krazati approval May 5, 2026, after failed NSCLC PFS trial.

What makes Bristol Myers Squibb unique

  • Mezigdomide plus carfilzomib beats Kd in SUCCESSOR-2 Phase 3 PFS for RRMM.
  • Sotyktu gains EU approval May 2026 for psoriatic arthritis post-POETYK trials.
  • Cobenfy switch study shows 8-week PANSS stability from atypicals in schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

INACTIVE